NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Hepatitis C, Chronic

Countries: Germany

This multicenter, observational study will assess the efficacy and the safety of Pegasys (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C. Patients will receive Pegasys and/or ribavirin and/or a protease inhibitor according to local guidelines. Data will be collected for 96 weeks.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Diagnosis of chronic hepatitis C
* Patients receiving treatment with Pegasys and/or Copegus (ribavirin) and/or a protease inhibitor according to local label

Exclusion Criteria:

* Contraindications against Pegasys or Copegus
* Not willing or unable to sign written informed consent form

Locations (2)

Hanover, Germany
Herne, Germany